Literature DB >> 27401739

Aliskiren suppresses atrial electrical and structural remodeling in a canine model of atrial fibrillation.

Akira Satoh1, Shinichi Niwano2, Hiroe Niwano3, Jun Kishihara2, Yuya Aoyama2, Jun Oikawa2, Hidehira Fukaya2, Hideaki Tamaki4, Junya Ako2.   

Abstract

Aliskiren, a direct renin inhibitor is expected to achieve sufficient suppression of renin-angiotensin system. We evaluated the effect of aliskiren on the electrical and structural remodeling in a canine atrial fibrillation (AF) model. Twenty-eight dogs were divided into three groups: (1) pacing control group (n = 12), with continuous atrial rapid pacing for 3 or 6 weeks, (2) pacing + aliskiren group (n = 12), with oral aliskiren (30 mg/kg/day), and (3) sham group (n = 4), no pacing nor drug administration. Electrophysiological properties and AF inducibility were evaluated every week. After the protocol, the left atrial tissue was sampled for the further histological and mRNA analysis. The electrical remodeling, AF inducibility, the left atrial enlargement and interstitial fibrosis were observed in pacing control group and were more prominent in the 6-week protocol (vs. 3 week, p < 0.05). The mRNA expressions of matricellular proteins exhibited upregulation in 3-week pacing control, but these upregulations became insignificant in 6 weeks. In contrast, collagen type 3 exhibited significant upregulation in 6 week but not in 3-week protocol. These changes were suppressed in the pacing + aliskiren group. Aliskiren suppressed the atrial remodeling in a canine AF model. This effect was accompanied by the suppression of tissue fibrosis.

Entities:  

Keywords:  Aliskiren; Atrial fibrillation; Atrial remodeling; Fibronectin1; Fibrosis

Mesh:

Substances:

Year:  2016        PMID: 27401739     DOI: 10.1007/s00380-016-0874-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  32 in total

1.  Bepridil inhibits sub-acute phase of atrial electrical remodeling in canine rapid atrial stimulation model.

Authors:  Daisuke Sato; Shinichi Niwano; Ryuta Imaki; Yoshihiko Masaki; Sae Sasaki; Masaru Yuge; Shoji Hirasawa; Takeshi Sasaki; Masahiko Moriguchi; Hiroe Niwano; Hirokuni Yoshimura; Tohru Izumi
Journal:  Circ J       Date:  2006-02       Impact factor: 2.993

2.  Biosynthesis and processing of fibronectin in NIL.8 hamster cells.

Authors:  M G Choi; R O Hynes
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

3.  Effect of irbesartan on development of atrial fibrosis and atrial fibrillation in a canine atrial tachycardia model with left ventricular dysfunction, association with p53.

Authors:  Naoya Kataoka; Kunihiro Nishida; Koshi Kinoshita; Tamotsu Sakamoto; Yosuke Nakatani; Yasushi Tsujino; Koichi Mizumaki; Hiroshi Inoue; Koichiro Kinugawa
Journal:  Heart Vessels       Date:  2016-05-28       Impact factor: 2.037

Review 4.  The renin-angiotensin system: a therapeutic target in atrial fibrillation.

Authors:  Vishnu Patlolla; Alawi A Alsheikh-Ali; Amin M Al-Ahmad
Journal:  Pacing Clin Electrophysiol       Date:  2006-09       Impact factor: 1.976

5.  How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

Authors:  R J MacFadyen; A F Lee; J J Morton; S D Pringle; A D Struthers
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

6.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

7.  Incidence and predictors of ischemic stroke during hospitalization for congestive heart failure.

Authors:  Yasuhiro Hamatani; Moritake Iguchi; Michikazu Nakamura; Ryo Ohtani; Yugo Yamashita; Daisuke Takagi; Takashi Unoki; Mitsuru Ishii; Nobutoyo Masunaga; Hisashi Ogawa; Mio Hamatani; Mitsuru Abe; Masaharu Akao
Journal:  Heart Vessels       Date:  2015-07-29       Impact factor: 2.037

8.  Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model.

Authors:  Hideko Nakashima; Koichiro Kumagai
Journal:  Circ J       Date:  2007-12       Impact factor: 2.993

9.  Incidence of ischemic stroke and systemic embolism in patients with hypertrophic cardiomyopathy, nonvalvular atrial fibrillation, CHA2DS2-VASc score of ≤1 and without anticoagulant therapy.

Authors:  Yin-Jian Yang; Jin-Qing Yuan; Chao-Mei Fan; Jie-Lin Pu; Pi-Hua Fang; Jian Ma; Xi-Ying Guo; Yi-Shi Li
Journal:  Heart Vessels       Date:  2015-08-01       Impact factor: 2.037

10.  Valsartan for prevention of recurrent atrial fibrillation.

Authors:  Marcello Disertori; Roberto Latini; Simona Barlera; Maria Grazia Franzosi; Lidia Staszewsky; Aldo Pietro Maggioni; Donata Lucci; Giuseppe Di Pasquale; Gianni Tognoni
Journal:  N Engl J Med       Date:  2009-04-16       Impact factor: 91.245

View more
  7 in total

1.  Linagliptin prevents atrial electrical and structural remodeling in a canine model of atrial fibrillation.

Authors:  Tazuru Igarashi; Shinichi Niwano; Hiroe Niwano; Tomoharu Yoshizawa; Hironori Nakamura; Hidehira Fukaya; Tamami Fujiishi; Naruya Ishizue; Akira Satoh; Jun Kishihara; Masami Murakami; Junya Ako
Journal:  Heart Vessels       Date:  2018-05-02       Impact factor: 2.037

Review 2.  Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification.

Authors:  Hui Tao; Zheng-Yu Song; Xuan-Sheng Ding; Jing-Jing Yang; Kai-Hu Shi; Jun Li
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 3.  The complexity of atrial fibrillation newly diagnosed after ischemic stroke and transient ischemic attack: advances and uncertainties.

Authors:  Joshua O Cerasuolo; Lauren E Cipriano; Luciano A Sposato
Journal:  Curr Opin Neurol       Date:  2017-02       Impact factor: 5.710

4.  Relationship Between 25-Hydroxyvitamin D, Renin, and Collagen Remodeling Biomarkers in Atrial Fibrillation.

Authors:  Dimpi Patel; Aleksander Druck; Debra Hoppensteadt; Vinod Bansal; Yevgeniy Brailovsky; Mushabbar Syed; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

5.  Effect of c-Ski on atrial remodelling in a rapid atrial pacing canine model.

Authors:  Juan Wang; Min Han; Su-Xia Han; Cuiju Zhi; Suli Gao; Yao Li
Journal:  J Cell Mol Med       Date:  2019-12-09       Impact factor: 5.310

6.  Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.

Authors:  Ryo Nishinarita; Shinichi Niwano; Hiroe Niwano; Hironori Nakamura; Daiki Saito; Tetsuro Sato; Gen Matsuura; Yuki Arakawa; Shuhei Kobayashi; Yuki Shirakawa; Ai Horiguchi; Naruya Ishizue; Tazuru Igarashi; Tomoharu Yoshizawa; Jun Oikawa; Yoshinobu Hara; Takafumi Katsumura; Jun Kishihara; Akira Satoh; Hidehira Fukaya; Hiroyuki Sakagami; Junya Ako
Journal:  J Am Heart Assoc       Date:  2021-01-05       Impact factor: 5.501

7.  Fibronectin 1 inhibits the apoptosis of human trophoblasts by activating the PI3K/Akt signaling pathway.

Authors:  Jinlong Ji; Liping Chen; Yanyan Zhuang; Yun Han; Weichun Tang; Fei Xia
Journal:  Int J Mol Med       Date:  2020-09-23       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.